world1 outlet covering this

FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

First publishedMay 8, 18:21 UTC

Last updatedJul 12, 12:32 UTC · 12m ago

↻

each logo = when that outlet publishedlast updated on Braven

Story signals

How strong is this topic?

High significance means broad impact or urgency. Source trust reflects the average authority of outlets covering the story.

Significance5.3

Weighted from impact, urgency, coverage breadth, and topic sensitivity.

Source trust10.0

Average reliability level of outlets included in this topic.

Outlets1

Independent sources contributing to this topic cluster.

More outlets usually means a more confirmed developing story.

The report

FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.

Read the full report at FDA ↗

Related in the knowledge graph

organizationBizengri organizationFDA Grants Seventh Approval organizationNational Priority Voucher Pilot organizationProgram. FDA

Sources (1)

Avg source rating 10.0/10

FDA10